全文获取类型
收费全文 | 1275165篇 |
免费 | 94146篇 |
国内免费 | 1984篇 |
专业分类
耳鼻咽喉 | 18185篇 |
儿科学 | 42257篇 |
妇产科学 | 37812篇 |
基础医学 | 186989篇 |
口腔科学 | 35380篇 |
临床医学 | 108105篇 |
内科学 | 251435篇 |
皮肤病学 | 26497篇 |
神经病学 | 99181篇 |
特种医学 | 49984篇 |
外国民族医学 | 366篇 |
外科学 | 197581篇 |
综合类 | 26517篇 |
现状与发展 | 1篇 |
一般理论 | 300篇 |
预防医学 | 92610篇 |
眼科学 | 29056篇 |
药学 | 97761篇 |
1篇 | |
中国医学 | 2496篇 |
肿瘤学 | 68781篇 |
出版年
2018年 | 11810篇 |
2015年 | 11610篇 |
2014年 | 15994篇 |
2013年 | 24345篇 |
2012年 | 33543篇 |
2011年 | 35935篇 |
2010年 | 21207篇 |
2009年 | 20019篇 |
2008年 | 34973篇 |
2007年 | 37943篇 |
2006年 | 38504篇 |
2005年 | 37799篇 |
2004年 | 36378篇 |
2003年 | 35369篇 |
2002年 | 34920篇 |
2001年 | 58095篇 |
2000年 | 59584篇 |
1999年 | 50689篇 |
1998年 | 14232篇 |
1997年 | 12809篇 |
1996年 | 13071篇 |
1995年 | 12345篇 |
1994年 | 11758篇 |
1993年 | 10860篇 |
1992年 | 40984篇 |
1991年 | 40358篇 |
1990年 | 39885篇 |
1989年 | 38706篇 |
1988年 | 36108篇 |
1987年 | 35349篇 |
1986年 | 33723篇 |
1985年 | 32134篇 |
1984年 | 23922篇 |
1983年 | 20818篇 |
1982年 | 12377篇 |
1981年 | 10927篇 |
1980年 | 10204篇 |
1979年 | 22635篇 |
1978年 | 15877篇 |
1977年 | 13729篇 |
1976年 | 12970篇 |
1975年 | 14201篇 |
1974年 | 16682篇 |
1973年 | 16076篇 |
1972年 | 15318篇 |
1971年 | 14229篇 |
1970年 | 13215篇 |
1969年 | 12731篇 |
1968年 | 11978篇 |
1967年 | 10479篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
A. Hochsprung S. Escudero-Uribe A.J. Ibáñez-Vera G. Izquierdo-Ayuso 《Neurología (Barcelona, Spain)》2021,36(6):433-439
IntroductionPain is highly prevalent in patients with multiple sclerosis (MS); it is chronic in 50% of cases and is classified as nociceptive, neuropathic, or mixed-type. Pain affects quality of life, sleep, and the activities of daily living. Electrotherapy is an interesting alternative or complementary treatment in the management of pain in MS, with new innovations constantly appearing.Material and methodsThis study evaluates the effectiveness of treatment with monopolar dielectric transmission of pulsed electromagnetic fields (PEMF) for pain associated with MS. We performed a randomised, placebo-controlled clinical trial including 24 patients, who were assessed with the Brief Pain Inventory, the Multiple Sclerosis International Quality of Life questionnaire, the Beck Depression Inventory, and the Modified Fatigue Impact Scale.ResultsStatistically significant improvements were observed in maximum and mean pain scores, as well as in the impact of pain on work, personal relationships, and sleep and rest. Not significant differences were found between the treatment and placebo groups.ConclusionsTreatment with PEMF may be effective in reducing pain in patients with MS, although further research is necessary to confirm its effectiveness over placebo and to differentiate which type of pain may be more susceptible to this treatment. 相似文献
102.
Clinical Spectrum of Capillary Malformation–Arteriovenous Malformation Syndrome Presenting to a Pediatric Dermatology Practice: A Retrospective Study 下载免费PDF全文
Nicole A. Weitz M.D. Christine T. Lauren M.D. Gerald G. Behr M.D. June K. Wu M.D. Jessica J. Kandel M.D. Philip M. Meyers M.D. Sally Sultan M.D. Kwame Anyane‐Yeboa M.D. Kimberly D. Morel M.D. Maria C. Garzon M.D. 《Pediatric dermatology》2015,32(1):76-84
Capillary malformation–arteriovenous malformation syndrome (CM‐AVM) is an autosomal dominant disorder caused by RASA1 mutations. The prevalence and phenotypic spectrum are unknown. Evaluation of patients with multiple CMs is challenging because associated AVMs can be life threatening. The objective of this study was to describe the clinical characteristics of children presenting with features of CM‐AVM to an academic pediatric dermatology practice. After institutional review board approval was received, a retrospective chart review was performed of patients presenting between 2009 and 2012 with features of CM‐AVM. We report nine cases. Presenting symptoms ranged from extensive vascular stains and cardiac failure to CMs noted incidentally during routine skin examination. All demonstrated multiple CMs, two had Parkes Weber syndrome, and two had multiple infantile hemangiomas. Seven patients had family histories of multiple CMs; three had family histories of large, atypical CMs. Six had personal or family histories of AVMs. Genetic evaluation was recommended for all and was pursued by six families; four RASA1 mutations were identified, including one de novo. Consultations with neurology, cardiology, and orthopedics were recommended. Most patients (89%) have not required treatment to date. CM‐AVM is an underrecognized condition with a wide clinical spectrum that often presents in childhood. Further evaluation may be indicated in patients with multiple CMs. This study is limited by its small and retrospective nature. 相似文献
103.
104.
105.
Implications for Practice
Breast cancer is far more curable than in the past but requires multimodality treatment. Great care must be taken to use the least leukemogenic treatment programs that do not sacrifice efficacy. Elimination of radiation and anthracycline/alkylating agent regimens will be helpful where possible, particularly in younger patients and possibly those with homologous repair deficiency (HRD). Use of colony-stimulating factors should be limited to those who truly require them for safe chemotherapy administration. Further study of a possible leukemogenic association with HRD and the various forms of colony-stimulating factors is badly needed.106.
107.
108.
109.
Adeline Tarantini Sylvie Huet Gérard Jarry Rachelle Lanceleur Martine Poul Ana Tavares Nádia Vital Henriqueta Louro Maria João Silva Valérie Fessard 《Environmental and molecular mutagenesis》2015,56(2):218-227
Synthetic amorphous silica (SAS) in its nanosized form is now used in food applications although the potential risks for human health have not been evaluated. In this study, genotoxicity and oxidative DNA damage of two pyrogenic (NM‐202 and 203) and two precipitated (NM‐200 and ‐201) nanosized SAS were investigated in vivo in rats following oral exposure. Male Sprague Dawley rats were exposed to 5, 10, or 20 mg/kg b.w./day for three days by gavage. DNA strand breaks and oxidative DNA damage were investigated in seven tissues (blood, bone marrow from femur, liver, spleen, kidney, duodenum, and colon) with the alkaline and the (Fpg)‐modified comet assays, respectively. Concomitantly, chromosomal damage was investigated in bone marrow and in colon with the micronucleus assay. Additionally, malondialdehyde (MDA), a lipid peroxidation marker, was measured in plasma. When required, a histopathological examination was also conducted. The results showed neither obvious DNA strand breaks nor oxidative damage with the comet assay, irrespective of the dose and the organ investigated. Similarly, no increases in chromosome damage in bone marrow or lipid peroxidation in plasma were detected. However, although the response was not dose‐dependent, a weak increase in the percentage of micronucleated cells was observed in the colon of rats treated with the two pyrogenic SAS at the lowest dose (5 mg/kg b.w./day). Additional data are required to confirm this result, considering in particular, the role of agglomeration/aggregation of SAS NMs in their uptake by intestinal cells. Environ. Mol. Mutagen. 56:218–227, 2015. © 2014 Wiley Periodicals, Inc. 相似文献
110.